22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › DAY ONE BIOPHARMACEUTICALS INC. › 2024-2025

DAY ONE BIOPHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 171Asset managers, any item
  • 906Fund votes
  • June 2, 2025Meeting date

Results at a glance

Meeting of June 2, 2025: 4 items on DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025: 4 passed (calculated).

Dissent

Significant dissent: 1 director (21.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore DAY ONE BIOPHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by DAY ONE BIOPHARMACEUTICALS INC.

These tallies are DAY ONE BIOPHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

DAY ONE BIOPHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 2, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Natalie Holles 81,975,302---- 1,357,0276,470,934 98%Passed (calculated)—
Elect Director: Garry Nicholson, M.B.A. 65,553,238---- 17,779,0916,470,934 79%Passed (calculated)—
2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. 89,705,03374,95123,279 ---- 99.9%Passed (calculated)—
3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. 82,385,592879,95766,780 --6,470,934 99%Passed (calculated)—

Source: DAY ONE BIOPHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.

How asset managers voted at the DAY ONE BIOPHARMACEUTICALS INC. 2024-2025 meeting

171 asset managers disclosed a vote on at least one DAY ONE BIOPHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Garry Nicholson, M.B.A.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 65,553,238WITHHELD: 17,779,091
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Election of Class I Directors: Garry Nicholson

DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Garry Nicholson, M.B.A.”): 65,553,238 for, 17,779,091 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 22,866,484 for, 1,239,733 withheld, 104,089 abstained.

FOR
FOR: 22,866,484ABSTAIN: 104,089WITHHOLD: 1,239,733
Largest asset managers voting on “Election of Class I Directors: Garry Nicholson” at DAY ONE BIOPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,729,5920 00For
Vanguard5,825,8130 00For
FRANKLIN STRATEGIC SERIES2,334,1420 00For
BlackRock2,169,4980 00For
T. Rowe Price756,5200 00For
Charles Schwab527,9870 00For
Dimensional00 0379,585Withhold
State Street3350 0154,122Withhold
Equitable85,9950 062,790Mixed
TIAA137,8460 00For
Delaware/Macquarie00 0110,000Withhold
Tema ETF Trust92,0230 00For
QUANTITATIVE MASTER SERIES LLC85,9500 00For
WisdomTree00 077,906Withhold
Lincoln Financial00 076,829Withhold
ALPS ETF Trust00 067,343Withhold
SEI00 066,100Withhold
Exchange Place Advisors Trust00 49,8570Abstain
MASTER INVESTMENT PORTFOLIO40,7510 00For
ProShares00 038,925Withhold
Northern Trust00 032,325Withhold
Global X00 032,210Withhold
Direxion Shares ETF Trust00 028,227Withhold
JPMorgan24,8360 00For
John Hancock00 21,1880Abstain

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

Elect Director: Natalie Holles

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 81,975,302WITHHELD: 1,357,027
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Election of Class I Directors: Natalie Holles

DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Natalie Holles”): 81,975,302 for, 1,357,027 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 23,717,591 for, 473,269 withheld, 19,446 abstained.

FOR
FOR: 23,717,591ABSTAIN: 19,446WITHHOLD: 473,269
Largest asset managers voting on “Election of Class I Directors: Natalie Holles” at DAY ONE BIOPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,729,5920 00For
Vanguard5,825,8130 00For
FRANKLIN STRATEGIC SERIES2,334,1420 00For
BlackRock2,169,4980 00For
T. Rowe Price756,5200 00For
Charles Schwab527,9870 00For
Dimensional00 0379,585Withhold
State Street154,4570 00For
Equitable85,9950 062,790Mixed
TIAA137,8460 00For
Delaware/Macquarie110,0000 00For
Tema ETF Trust92,0230 00For
QUANTITATIVE MASTER SERIES LLC85,9500 00For
WisdomTree77,9060 00For
Lincoln Financial73,3290 03,500For
ALPS ETF Trust67,3430 00For
SEI66,1000 00For
Exchange Place Advisors Trust49,8570 00For
MASTER INVESTMENT PORTFOLIO40,7510 00For
ProShares38,9250 00For
Northern Trust32,3250 00For
Global X32,2100 00For
Direxion Shares ETF Trust28,2270 00For
JPMorgan24,8360 00For
John Hancock19,8510 1,3370Mixed

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 82,385,592AGAINST: 879,957

Prior year: 99.2% for (May 23, 2024 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 171 asset managers

Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.”): 82,385,592 for, 879,957 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 54 asset managers voting on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at DAY ONE BIOPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,729,5920 00For
Vanguard5,825,8130 00For
FRANKLIN STRATEGIC SERIES2,334,1420 00For
BlackRock2,169,4980 00For
T. Rowe Price756,5200 00For
Charles Schwab527,9870 00For
Dimensional379,5850 00For
State Street154,4570 00For
Equitable148,7850 00For
TIAA137,8460 00For
Delaware/Macquarie110,0000 00For
Tema ETF Trust92,0230 00For
QUANTITATIVE MASTER SERIES LLC85,9500 00For
WisdomTree77,9060 00For
Lincoln Financial76,8290 00For
ALPS ETF Trust67,3430 00For
SEI66,1000 00For
Exchange Place Advisors Trust49,8570 00For
MASTER INVESTMENT PORTFOLIO40,7510 00For
ProShares38,9250 00For
Northern Trust32,3250 00For
Global X32,2100 00For
Direxion Shares ETF Trust28,2270 00For
JPMorgan24,8360 00For
John Hancock21,1880 00For

Fund voting reports, all 54 managers: 24,189,860 for, 1,049 against, 19,397 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 135 asset managers voting on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at DAY ONE BIOPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,119,1850 00For
Atlas Venture Life Science Advisors, LLC6,430,2570 00For
RA CAPITAL MANAGEMENT, L.P.4,913,3270 00For
FRANKLIN ADVISERS INC3,935,6830 00For
PICTET ASSET MANAGEMENT SA3,348,4660 00For
Estuary Capital Management LP3,318,4060 00For
DEERFIELD MANAGEMENT COMPANY, L.P.2,753,5570 00For
BRAIDWELL LP2,113,3230 00For
BlackRock1,945,4130 00For
Alyeska Investment Group, L.P.1,865,6840 00For
Vestal Point Capital, LP1,736,7480 00For
GEODE CAPITAL MANAGEMENT, LLC1,529,9200 00For
T. Rowe Price1,128,5050 00For
State Street1,003,2400 00For
EcoR1 Capital, LLC862,0680 00For
DAFNA Capital Management LLC761,3630 00For
MARSHALL WACE, LLP662,1970 00For
Charles Schwab527,9980 00For
Hudson Bay Capital Management LP430,8140 00For
Northern Trust377,5670 00For
Stonepine Capital Management, LLC364,2380 00For
UniSuper Management Pty Ltd350,0000 00For
Citadel294,9360 00For
AQR294,7800 00For
NOMURA ASSET MANAGEMENT CO LTD249,6250 00For

Institutional-manager reports, all 135 managers: 55,918,462 for, 207,811 against, 106 not voted. Showing the 25 largest; every one is in the interactive database (link above).

2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 89,705,033AGAINST: 74,951

Prior year: 99.9% for (May 23, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.

DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”): 89,705,033 for, 74,951 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 24,190,909 for, 19,397 abstained.

FOR
FOR: 24,190,909ABSTAIN: 19,397
Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at DAY ONE BIOPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,729,5920 00For
Vanguard5,825,8130 00For
FRANKLIN STRATEGIC SERIES2,334,1420 00For
BlackRock2,169,4980 00For
T. Rowe Price756,5200 00For
Charles Schwab527,9870 00For
Dimensional379,5850 00For
State Street154,4570 00For
Equitable148,7850 00For
TIAA137,8460 00For
Delaware/Macquarie110,0000 00For
Tema ETF Trust92,0230 00For
QUANTITATIVE MASTER SERIES LLC85,9500 00For
WisdomTree77,9060 00For
Lincoln Financial76,8290 00For
ALPS ETF Trust67,3430 00For
SEI66,1000 00For
Exchange Place Advisors Trust49,8570 00For
MASTER INVESTMENT PORTFOLIO40,7510 00For
ProShares38,9250 00For
Northern Trust32,3250 00For
Global X32,2100 00For
Direxion Shares ETF Trust28,2270 00For
JPMorgan24,8360 00For
John Hancock21,1880 00For

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

Largest DAY ONE BIOPHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,389,859 shares outstanding at the time of that meeting.

Fund voting reports: top DAY ONE BIOPHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 12.28%
2Vanguard 6.67%
3FRANKLIN STRATEGIC SERIES 2.67%
4BlackRock 2.48%
5T. Rowe Price 0.87%
6Charles Schwab 0.60%
7Dimensional 0.43%
8State Street 0.18%
9Equitable 0.17%
10TIAA 0.16%
Institutional-manager reports: top DAY ONE BIOPHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 13.87%
2Atlas Venture Life Science Advisors, LLC 7.36%
3RA CAPITAL MANAGEMENT, L.P. 5.62%
4FRANKLIN ADVISERS INC 4.50%
5PICTET ASSET MANAGEMENT SA 3.83%
6Estuary Capital Management LP 3.80%
7DEERFIELD MANAGEMENT COMPANY, L.P. 3.15%
8BRAIDWELL LP 2.42%
9BlackRock 2.23%
10Alyeska Investment Group, L.P. 2.13%

Reported DAY ONE BIOPHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

DAY ONE BIOPHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
AI Day 1 LLC13,756,908 15.74%Proxy statement (DEF 14A), proxy filed April 11, 2025
FMR (Fidelity)13,700,448 15.68%Form 13F, quarter ended March 31, 2025
Fidelity12,887,467 14.75%Proxy statement (DEF 14A), proxy filed April 11, 2025
BlackRock6,757,929 7.73%Form 13F, quarter ended March 31, 2025
Entities affiliated with Atlas Venture6,430,257 7.36%Proxy statement (DEF 14A), proxy filed April 11, 2025
Vanguard Group5,943,243 6.80%Form 13F, quarter ended March 31, 2025
RA Capital Management, L.P.5,755,577 6.59%Proxy statement (DEF 14A), proxy filed April 11, 2025
Glazer Capital, LLC5,615,390 6.43%Schedule 13G, filed March 19, 2026
Franklin Templeton4,018,370 4.60%Form 13F, quarter ended March 31, 2025
Jeremy Bender, Ph.D., M.B.A.3,800,495 4.35%Proxy statement (DEF 14A), proxy filed April 11, 2025

Percentages above are of 87,389,859 shares outstanding, as reported by DAY ONE BIOPHARMACEUTICALS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At DAY ONE BIOPHARMACEUTICALS INC.'s shareholder meeting held June 2, 2025, in the 2024-2025 proxy season, 171 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 906 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: DAY ONE BIOPHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DAY ONE BIOPHARMACEUTICALS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

DAY ONE BIOPHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Cite this page

Proxy Votes Now, “DAY ONE BIOPHARMACEUTICALS INC. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/day-one-biopharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.